Internal Medicine Department, The Animal Medical Center, New York, NY 10065, USA.
J Vet Intern Med. 2012 Mar-Apr;26(2):363-9. doi: 10.1111/j.1939-1676.2011.00864.x. Epub 2012 Feb 1.
Anemia is present in 30-65% in cats with chronic kidney disease (CKD) and few long-term treatment options exist. Darbepoetin is effective in treating anemia of kidney disease in humans and may be used in cats.
HYPOTHESIS/OBJECTIVE: To evaluate the use of darbepoetin, a recombinant analog of human erythropoietin, to stimulate erythropoiesis, and to effectively treat anemia of kidney disease in cats.
Twenty-five of 66 cats that received ≥ 2 doses of darbepoetin at the Animal Medical Center between January 2005 and December 2009 were included in this study.
Cats were included in the study if they received darbepoetin and follow-up data were available for at least 56 days and had CKD as a primary clinical diagnosis. Cats were excluded if they were treated with darbepoetin but did not have kidney disease. Response to treatment was defined as reaching or exceeding a target packed red blood cell volume or hematocrit of 25%.
Fourteen of 25 cats responded. Thirteen of those 14 cats received a dosage of 1 μg/kg/wk or higher. Presumptive adverse effects included vomiting, hypertension, seizures, and fever.
Darbepoetin is effective for treatment of anemia of kidney disease in cats. Pure red cell aplasia appears to be less common with darbepoetin than with epoetin usage.
患有慢性肾脏病（CKD）的猫中，有 30-65%存在贫血，且几乎没有长期的治疗选择。达贝泊汀在治疗人类肾脏疾病性贫血方面有效，可能也适用于猫。
假设/目的：评估使用重组人促红细胞生成素类似物达贝泊汀刺激红细胞生成并有效治疗猫肾脏疾病性贫血。
2005 年 1 月至 2009 年 12 月期间，在动物医疗中心接受至少 2 次达贝泊汀治疗的 66 只猫中，有 25 只被纳入本研究。
如果猫接受了达贝泊汀治疗且至少有 56 天的随访数据，并且 CKD 是主要临床诊断，则将其纳入研究。如果猫接受了达贝泊汀治疗但没有肾脏疾病，则将其排除在外。治疗反应定义为达到或超过目标红细胞比容或红细胞压积 25%。
25 只猫中有 14 只出现反应。这 14 只猫中有 13 只接受了 1 μg/kg/wk 或更高的剂量。推测的不良反应包括呕吐、高血压、癫痫发作和发热。
达贝泊汀治疗猫肾脏疾病性贫血有效。与使用促红细胞生成素相比，纯红细胞再生障碍似乎较少见。
